title: Porcine factor VIII: past, present and future.
abstract: Porcine factor VIII concentrate is effective in up to 90% of bleeds. Its use is, however, sometimes associated with reactions and a fall in platelet count Furthermore, it is not virally attenuated, although no viral transmission from this product to humans has ever been demonstrated. A third-generation porcine factor VIII is currently being developed. This is purified from parvovirus-free porcine plasma using immunoaffinity and ion-exchange chromatography. It is virally attenuated using the solvent detergent method. It should have a very high specific activity and be virtually free of porcine von Willebrand factor. These product characteristics should confer greater product safety and a greatly reduced risk of treatment side effects.
authors.affiliation: University Dept. of Haematology, Manchester Royal Infirmary, UK. haemophilia@man.ac.uk
authors.forename: C R
authors.initials: CR
authors.lastname: Hay
mesh_terms: D000818:Animals; D003257:Consumer Product Safety; D005169:Factor VIII / Q000302:isolation & purification* / Q000627:therapeutic use; D006405:Hematology / Q000639:trends; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007518:Isoantibodies / Q000097:blood; D013552:Swine
chemical_list: D007518:Isoantibodies; D005169:Factor VIII